After reporting solid safety results for umbralisib as a monotherapy in chronic lymphocytic leukemia (CLL) patients who are intolerant to prior BTK (Imbruvica) or PI3K delta inhibitor (Zydelig) therapy, TG Therapeutics (NASDAQ:TGTX) 10.8% on Monday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,